Prevalence of Anti-SARS-CoV-2 Antibodies and Associated Factors Among Health Care Workers in Santiago De Cali, Colombia.
SARS-CoV-2
antibodies
epidemiology
health care workers
seroprevalence
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
11
2022
accepted:
14
01
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
4
3
2023
Statut:
epublish
Résumé
This study aims to determine the seroprevalence of coronavirus disease (COVID-19) among health care workers and describe the associated sociodemographic and labor features. An observational study with an analytical component was conducted at a clinic in Cali, Colombia. The sample size was 708 health workers and they were selected by stratified random sampling. A Bayesian analysis was developed to determine the raw and adjusted prevalence. A Poisson regression model was used to estimate the prevalence ratios. Overall seroprevalence of COVID-19 among healthcare workers was 29%. Miscellaneous services workers, healthcare, and administrative workers, was 38%, 33%, and 32%, respectively. Factors related to seropositivity were having a contact with a COVID-19 patient for >120 minutes and being diagnosed with COVID-19 by laboratory tests. The present study shows a adjusted seroprevalence of 29% in health workers, indicating a high level of disease transmission and an increased risk of infection in this population group.
Identifiants
pubmed: 36866168
doi: 10.2147/IJGM.S396357
pii: 396357
pmc: PMC9970879
doi:
Types de publication
Journal Article
Langues
eng
Pagination
697-705Informations de copyright
© 2023 Osorio-Toro et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Am J Ind Med. 2021 Apr;64(4):227-237
pubmed: 33491195
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Lancet. 2017 Mar 25;389(10075):1190-1191
pubmed: 28353437
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Salud Publica Mex. 2022 Jul 08;64(4, jul-ago):348-356
pubmed: 36130357
Am J Infect Control. 2021 Oct;49(10):1334-1336
pubmed: 34375702
Int J Infect Dis. 2021 Jan;102:285-288
pubmed: 33157290
Int J Infect Dis. 2020 Dec;101:314-322
pubmed: 33045429
Public Health. 2021 Sep;198:102-105
pubmed: 34411992
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
Clin Microbiol Infect. 2021 Dec;27(12):1762-1771
pubmed: 34582980
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930
J Med Virol. 2020 Oct;92(10):2004-2010
pubmed: 32330303
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Rev Salud Publica (Bogota). 2023 Feb 6;22(2):123-131
pubmed: 36753100
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
JAMA. 2022 Mar 15;327(11):1085-1087
pubmed: 35113143
Int J Environ Res Public Health. 2021 Jul 27;18(15):
pubmed: 34360241
Biomedica. 2017 Dec 01;37(4):577-589
pubmed: 29373777
Nature. 2021 Feb;590(7846):382-384
pubmed: 33594289
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Lancet Infect Dis. 2021 Apr;21(4):473-481
pubmed: 33338441
Clin Biochem. 2021 Apr;90:15-22
pubmed: 33539808
Int J Environ Res Public Health. 2022 Jun 27;19(13):
pubmed: 35805539
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675